Shares of clinical stage biopharmaceutical company Aligos Therapeutics, Inc. (ALGS) are down 18 percent on Thursday's trading. The company priced its public offering of 4.4 million shares at $19.00 per share. All the shares are being offered by the company itself. Aligos expects to generate gross proceeds of $83.6 million from the offering, which will close on July 6.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Shares of clinical stage biopharmaceutical company Aligos Therapeutics, Inc. (ALGS) are down 18 percent on Thursday's trading. The company priced its public offering of 4.4 million shares at $19.00 per share. All the shares are being offered by the company itself. Aligos expects to generate gross proceeds of $83.6 million from the offering, which will close on July 6.

RTTNews | Jul 1, 2021 11:47AM EDT

11:47 Thursday, July 1, 2021 (RTTNews.com) - Shares of clinical stage biopharmaceutical company Aligos Therapeutics, Inc. (ALGS) are down 18 percent on Thursday's trading. The company priced its public offering of 4.4 million shares at $19.00 per share. All the shares are being offered by the company itself. Aligos expects to generate gross proceeds of $83.6 million from the offering, which will close on July 6.

Currently trading at $16.70, the stock has traded between $12.82 and $37.51 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3206513/aligos-therapeutics-shares-fall-18.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved